Patients With Intermittent Claudication Injected With ALDH Bright Cells

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

March 31, 2017

Conditions
Peripheral Artery DiseaseIntermittent Claudication
Interventions
BIOLOGICAL

ALD-301

Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh

BIOLOGICAL

Placebo (vehicle)

Ten 1ml injections of placebo in the index calf and posterior, lower thigh

Trial Locations (9)

32610

University of Florida-Department of Medicine, Gainesville

32806

Orlando Health Inc., Orlando

33101

University of Miami-Interdisciplinary Stem Cell Institute, Miami

40202

University of Louisville, Louisville

46202

Indiana Center for Vascular Biology and Medicine, Indianapolis

55407

Minneapolis Heart Institute Foundation, Minneapolis

55455

Clinical and Translational Science Institute at University of Minnesota, Minneapolis

77030

Texas Heart Institute, Houston

94305

Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Aldagen

INDUSTRY

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

The University of Texas Health Science Center, Houston

OTHER

NCT01774097 - Patients With Intermittent Claudication Injected With ALDH Bright Cells | Biotech Hunter | Biotech Hunter